1152961-27-7

Basic information

• Product Name: 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine
• Synonyms: 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine
• CAS NO: 1152961-27-7
• Molecular Formula: C9H16N4O
• Molecular Weight: 196.24954
• Mol File: 1152961-27-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine(1152961-27-7)
• EPA Substance Registry System: 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine(1152961-27-7)

Safety Data

• Hazardous Substances Data: 1152961-27-7(Hazardous Substances Data)

Usage

General Description

The chemical 1-(2-Morpholin-4-yl-ethyl)-1H-pyrazol-4-ylaMine, also known as 1-(2-Morpholin-4-yl-ethyl)pyrazole-4-amine, is a compound with the molecular formula C10H17N5O. It is a pyrazole derivative with a morpholine group attached to the nitrogen atom. This chemical is commonly used in pharmaceutical research and drug development due to its potential biological activities. It may have applications in the treatment of various medical conditions, although further research is needed to fully understand its properties and potential uses.

Upstream product

• 42802-94-8 4-(2-bromoethyl)morpholine hydrobromide 
• 957479-10-6 4-(2-(4-nitro-1Η-pyrazol-1-yl)ethyl)morpholine 
• 89583-07-3 N-(2-bromoethyl)morpholine 
• 622-40-2 2-(morpholin-4-yl)ethanol 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Relevant articles and documents

FGFR Inhibitor compounds and uses thereof

The invention relates to FGFR inhibitor compounds and uses thereof. , The application discloses a compound as shown in a formula (I). A compound, or an optical isomer, a geometric isomer, a tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The application further relates to the application of the compound in medicine.

ATF6 MODULATORS AND USES THEREOF

Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof

A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.